INTRODUCTION
Atrial Fibrillation (AF) is the most common arrhythmia in the United States. 1 The disease affects both genders, with a lifetime risk of 1 in 4 for both men and women over the age of 40 . 2 The risk of AF increases with age and as the elderly population increases, so will the prevalence of AF. 2 The prevalence of AF in the U.S. is projected to increase from 2.7 million in 2010 to 6 million by 2050. 3 AF alone is associated with a 4-to 5-fold increase risk of ischemic stroke, is attributable to 15% of strokes in persons <80, and 24% of ischemic strokes in person 80 to 89 years old. 4 In addition to ischemic stroke, patients with AF are at risk for other thrombotic events such as myocardial infarction (MI) and systemic embolism (SE).
The primary goal in treating AF is stroke prevention. The CHADS 2 score (Congestive heart failure, Hypertension, Age 75 or older, Diabetes, and history of Stroke) is a tool used to estimate risk of stroke and identify those patients who would most benefit from an anticoagulant. However, treatment with an anticoagulant is associated with increased risk of bleeding. Bleeding can be minor -a nosebleed or increased bruising -but there is risk of serious adverse events including gastrointestinal (GI) bleeds and intracranial hemorrhages (ICH), both of which necessitate hospitalization.
Healthcare utilization associated with AF is substantial and has been shown to be driven by hospitalizations. [5] [6] [7] [8] [9] Diagnosis with AF is associated with increased morbidity and mortality. [10] [11] [12] [13] [14] In the last several years three new anticoagulant options have come on to the market, altering the risk/benefit profile of stroke prevention therapy. In today's environment of limited resources, health technology assessment is an increasingly important aid to guiding resource use and is being used to compare treatment strategies in AF patients. [15] [16] [17] [18] [19] [20] [21] [22] P a g e | 2
The development of useful decision analytic models in atrial fibrillation (AF) is contingent on accurate estimates of costs. Estimated costs of AF include not only the cost of treating underlying AF, but also of treating the adverse clinical events occurring in the context of treatment. The safety and efficacy endpoints commonly used in AF clinical trials are ischemic stroke, MI, SE, ICH and GI bleed [23] [24] [25] [26] impactful and costly events leading to hospitalization and associated with high morbidity and mortality. 2,27-28 AF cost-effectiveness (CEA) models typically focus on modeling the risk-benefit of these five events but, to date, have not incorporated AF specific event costs. [15] [16] [17] [18] [19] [20] [21] [22] If costs of these events are different in the AF population than the general population from which the costs are derived, failure to incorporate AF specific costs may lead to over or under estimation of the cost-effectiveness of AF therapy options.
In AF, the traditional efficacy endpoint has been ischemic stroke and traditional safety endpoint bleeding events like ICH and GI bleed. To date, only two studies have quantified the incremental cost of ischemic stroke in patients with AF. These studies are of limited use in current research. One study used the Medicare 5% claims database, thereby limiting those included to patients over the 65 years of age and excluding out-of-pocket costs; 29 the other used health plan claims, but with cost data that is now more than a decade old. 30 Additionally, patients with previous stroke or bleed events were excluded from analysis possibly biasing results toward lower costs because prior history of stroke or bleed increases the risk of recurrent events and the subsequent cost of events. 29 In terms of safety endpoints, four claims-based studies have characterized incremental costs of bleeding events in the AF population. [29] [30] [31] [32] Two of these studies did not separate out ICH and GI bleed, reporting only composite major bleeds. 30, 32 The combination of severe and less severe bleeding events reduces interpretability of presented cost estimates and does not allow for direct interpretation with clinical trial data or allow for direct use in CEAs.
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Of the two studies that reported costs separately, one was in Medicare patients 29 and excluded out-of-pocket costs; the other used MarketScan Database. 31 The MarketScan analysis reported the annual percent increase in healthcare costs from baseline controls and annual total healthcare costs, but not the direct incremental cost of a bleed (GI or ICH) and did not report results for less than 12 months of follow-up. 31 Lack of incremental costs and reporting only 12 month totals, limits the translation of this research into CEA models. 
Study Cohort Identification
The study cohort consisted of adults ≥18 years old with the first diagnosis of AF between Table 1) Because duration of AF can affect medical costs, the study was limited to patients with incident AF.
Patient Characteristics
Demographic information including age, sex, type of insurer (employer versus health plan administrator), type of health plan and geographic region were assessed at index diagnosis.
Total inpatient and outpatient healthcare costs (paid claims and out-of-pocket patient payments) were captured during the baseline period. Comorbidities and risk factors were assessed during the baseline period. The risk of stroke was quantified using the CHADS 2 score 33 while the Deyo adaptation of the Charlson Comorbidity Index (CCI) 34 quantified comorbidity burden. (Table 1) The presence of comorbidities and risk factors was determined by at least one claim in the baseline period. Patients with previous ischemic or bleeding events were not excluded from the cohort instead, risk scores and total medical cost in the baseline period were adjusted for in the analysis.
Event Identification
Cases were identified as those AF patients who had an event of interest after the date of index diagnosis. All patients with incident AF were followed for first inpatient admission lasting greater than one day with a primary diagnosis of an event of interest using validated ICD-9 codes for administrative data. (Table 1 ) [35] [36] [37] [38] Patients were excluded if the event was due to traumatic brain injury since those events were assumed to not be due to AF. For ease of analysis, if patients had a second hospitalization for an event of interest within 365 days of the first admission they were also excluded. After the date of the event of interest was identified, continuous pharmacy and medical enrollment was assured for the following 12 months. Patients who died during their admission or who did not have 12 months of follow up were excluded.
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Matching
Cases were matched to controls in a 1:4 ratio using a greedy matching algorithm. Controls were subjects with AF but without an admission for an event of interest. Because disease duration can affect medical costs, it was important to match cases and controls on time between date of index diagnosis and date of event. To facilitate matching, a random date after AF diagnosis through 12/31/2010 was generated for the control group. The random date was used as a proxy for date of event of interest and used to match on months from AF diagnosis to month of event. Additionally, cases were matched to controls on gender, month of AF diagnosis, and geographic region. Age was intentionally not matched on to allow for analysis of the impact of age on medical costs. Unmatched cases and controls were excluded from final analysis.
Outcomes
The primary outcomes of interest were the incremental costs of each type of event of interest at 30, 90, and 365 days. Costs included all payer and out-of-pocket expenses for inpatient and outpatient claims; pharmacy claims were not included. Costs were inflated to 2012 US$. Control patients who did not have an event of interest were used to estimate the baseline cost of treating AF. The incremental cost of each event type was estimated as the difference in average costs between patients with events and their matched controls.
Statistical Analysis
Univariate, descriptive analyses were conducted to estimate means with standard deviations for continuous variables and counts with percentages for categorical variables by case and control. For bivariate analyses, total average costs for cases and matched controls were compared using a 2-sided, 2-sample t-test assuming unequal variance; and compared to use of a simple ordinary least squares (OLS) regression with robust standard errors. Both tests assumed a significance level of α=0.05. Stratified analyses were conducted to estimate costs at 30, 90, and 365 days.
To adjust for potential confounders that remained after matching, models estimating the incremental costs of events of interest were adjusted for the following covariates: age at AF diagnosis, CHADS 2 score, CCI score, baseline total inpatient and outpatient costs (including all claims and out-of-pocket payments), and type of health plan structure. Multivariate analyses were conducted using generalized linear modeling (GLM) and generalized estimating equations (GEE); multiple modeling techniques were used to allow model comparison for learning purposes. A flexible generalization of ordinary linear regression, GLM allows for dependent outcomes (in this case, cost variables) to have a non-normal distribution. GLM models require specification of a 'link' function to model the relationship between the dependent variable and the linear combination of independent variables and covariates, and an associated 'family' function to model the distribution of the dependent variable. Specifying GLM with the Gaussian distribution and identity link is the same as OLS.
Specifying the gamma distribution and log (transformation) link allows for the regression to take into account the impact of right skewed (non-normal distribution) nature of cost data and is commonly used in conducting cost analyses. GEE is a specific type of GLM that allows correlations in the data to be taken into account; the same links and distributions are specified. The matching process induces correlation (thereby violating assumptions of independence) and GEE accounts for this in the regression. GEE using the Gaussian distribution, identity link, and independent correlation structure was evaluated, and is also the same as OLS; GEE using the Gaussian distribution, identity link, and the exchangeable correlation structure accounts for the induced correlation. GEE specifying the gamma distribution, log link, and exchangeable correlation structure accounts for the skewed nature of the cost data, while also taking into account the correlated nature of our data. All multivariate analyses included the use of robust standard errors and assumed a significance P a g e | 8
level of α=0.05. All analyses were conducted using StataMP version 12.1 (StataCorp, College Station, TX).
RESULTS

Study Population
From Table 2 compares the characteristics of potential cases and potential controls and is categorized by variables included in the matching and those included in the regressions (non-matched). Gender was well balanced between cases and potential controls. As an entire cohort, cases and controls were largely covered under a non-employer administered plan (>70%) and from the South and North Central regions of the U.S.
(>53%). On average, the pre-matched cases were older (72:66 case:control), more often covered by comprehensive medical health plan, less often Fee-For-Service plan, and had a higher CHADS 2 Score and CCI Score. Matching was successfully completed on gender, health plan design and region, with only 4 cases not being matched. On average, cases had higher CHADS 2 and CCI scores compared to their controls.
Ischemic and Bleeding Events
All events were balanced by gender. (Table 2 Table 4 provides a detailed comparison of the incremental costs associated with each event of interest when using a variety of regression techniques. Moving forward, appropriate model selection depends on the skewed (non-normal) distribution of the dependent variable, costs as a continuous outcome, and accounting for correlation in data that is introduced via the matching process. Due to the correlation and non-normal continuous outcome, the appropriate models are GEE with log link, gamma distribution, and exchangeable correlation structure.
Model Selection
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DISCUSSION
This study characterized the incremental healthcare costs associated with key adverse events in newly diagnosed AF patients in the MarketScan Commercial Claims and Medicare
Coordination of Benefits Databases. The findings suggest that occurrence of an adverse event is rare but costly. After 365 days costs had not returned to baseline, supporting previous studies suggesting that financial impact of events of ischemic and hemorrhagic events last beyond the initial admission. These findings build on previous cost per ischemic and hemorrhagic event by characterizing the incremental cost of an event of interest.
Ischemic Events
To date, this is the first study to look at the incremental cost of all five events: stroke, MI, SE, ICH, and GI Bleed using the large MarketScan database and to include patient out-ofpocket costs in the estimates. Despite long standing evidence that strokes in the AF population are more severe than those in the non-AF population, there is limited data on the incremental cost of ischemic stroke in this population. 14 studies that ischemic stroke in AF is more costly than in the general population. 39 To date, no studies have characterized the incremental cost of SE and MI in the AF patient population. Therefore, this research presents an opportunity to add to the AF literature. MI has been characterized as costing about $18,000 for the initial hospitalization. 40 Our study suggests that an MI in patients with AF may be more costly, with an incremental cost of P a g e | 12
$32,535 at 30 days and $38,651 at 365 days after the event (2012 US$). Though the occurrence of SE's has been widely reported in clinical trials of AF, the costs have not been described in the literature. This study indicates that SE's are costly events, similar in magnitude to stroke and GI bleed and are an important healthcare cost in the AF population.
Bleeding Events
Our study is the first to characterize the incremental cost of different types of bleeding events in the AF population. We estimate the annual incremental cost of an ICH to be $77,513 (2012 US$). This estimate is higher than other incremental estimates in AF.
Mercaldi et al examined the annual incremental ICH costs in the Medicare 5% sample and obtained a lower estimate of $49,216 ($45,490-$53,431; 2011 USD). 29 Differences between
Mercaldi and this study may be due to differences in patient populations and the ability of this analysis to capture out-of-pocket expenses associated with long term care of patients after an ICH.
Our study found the mean incremental cost of a GI bleed to be $24,078 365 days after the GI bleed, compared to AF patients without an event. This is similar to other studies that have found mean cost of a GI bleed over 12 months to be $16,457 -$25,442. 29, 31 Overall, published data of events of interest in the AF patient population are limited.
Strengths and Limitations
There are a number of limitations associated with this database analysis. First, as a claims database, the analysis is inherently subject to a variety of limitations including nondifferential misclassification bias due to missing or inaccurate coding and the lack of information on severity of disease that must then be inferred from the presence or absence of other ICD-9-CM codes. Additionally, change in severity of disease is not directly P a g e | 13
ascertainable from ICD-9 codes. Second, as a claims database, the relationship between AF and bleeding and ischemic events must be inferred. Third, all observational studies are subject to a variety of types of bias, including healthy worker bias. Patients whose claims appear in a database such MarketScan, are those healthy enough to work and receive health insurance under a commercial plan, or have resources and health to be enrolled in a Medicare supplemental plan. Further, patients whose claims appear in the Marketscan database may reflect a socioeconomic status that is unique, in that they may be healthier and wealthier than the general population, due to their ability to purchase Medicare underestimates by an unknown degree. The lack of pharmacy claim data also prevented our analysis from taking into account warfarin exposure. Warfarin is a commonly used anticoagulant in AF, and is indicated to prevent stroke at the risk of increased bleeding. Though >60% of cases had a CHADS 2 of 2 or greater, indicating warfarin to be appropriate, ascertaining drug exposure was outside the scope of this analysis. Another limitation, inherent to our study design, was the exclusion criteria of multiple events of interest and requiring 365 days of follow-up after an event of interest. This criteria biases the sample towards healthier patients, in that, to live a year after an event of interest you must be healthy enough to survive. People who are able to survive for one year may have different costs than those who do not. Additionally, people who have multiple events may be sicker than those described in this sample and have higher costs, therefore the costs in this study likely underestimate the costs in patients with multiple events of interest. 29 Finally, inflation P a g e | 14
was not accounted for in this analysis meaning that costs presented may be underestimates of costs in today's dollars.
Strengths of this study include the costing of key AF associated adverse event in the AF patient population. Secondly, this study was able to capture out-of-pocket costs, an important component missing from many previously published studies and thus provide perspective of the patients as well as the payers. MarketScan contains data on persons <65, so despite the mean age of cases being 72, the sample did include non-Medicare subjects, increasing the generalizability of our results. Due to the large sample size and patient-level data we were also able to analyze costs at the level of the day and present costs at 30, 90, and 365 day intervals. The level of detail in the dataset and the sample size allowed for matching on month of diagnosis and month of event helping to compare patients at similar level of AF disease progression. An additional strength of our study is matching design, which allowed for analysis of the incremental cost of an event in a scientifically rigorous manner. Though we did not match on risk scores (CHADS 2 and CCI) they were adjusted for in regression analysis, thus helping ensure that health status at diagnosis was similar between cases and controls.
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CONCLUSION
The results of this study provide unique quantifications of the incremental 30, 90, and 365 day costs of ischemic stroke, MI, ICH, SE, and GI bleed in patients with AF. This analysis is the first to describe the incremental costs of all events of interest in AF, using a single dataset, as well as include out-of-pocket costs in the incremental estimations. This analysis also provides the first AF specific estimates of the cost of MI and SE in the AF patient population. A cost effectiveness model that takes into account the incremental costs of these key ischemic and hemorrhagic events is now possible, and can be used to more accurately inform the risk and benefit profile of AF.
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